Why infectious disease clincial trials fail

How smarter global trial design is changing the odds

Ari Dearnley, Clinical Operations Manager

Infectious disease (ID) research has never been more strategically important or more operationally complex. From antimicrobial resistance to emerging viral threats, biotechs developing anti-infectives, vaccines, and novel biologics are operating under intense scientific, regulatory, and time pressures.

Yet despite unprecedented innovation, infectious disease clinical trials continue to fail at disproportionately high rates. Not always because the science is flawed, but because trial design, patient access, and execution strategy are misaligned with the realities of infectious disease research.

For global biotechs, success increasingly depends not just on the molecule, but on choosing a CRO partner that understands how infectious disease trials truly work in practice.

The hidden reasons infectious disease trials fail

When an infectious disease program stalls, the causes are often structural rather than scientific.

Patient recruitment remains the single greatest bottleneck. Unlike chronic diseases, infectious diseases are episodic, geographically uneven, and often seasonal. Overly rigid inclusion criteria, poor site selection, or delayed startup can mean missing the narrow window when patients are available.

Trial design frequently underestimates real-world variability. Standard endpoints may not reflect regional standards of care. Comparator arms can become outdated mid-trial. Adaptive designs are discussed but not always operationalised effectively.

Operational complexity is underestimated. ID trials often require rapid enrolment, tight sample-handling windows, cold-chain logistics, and coordination across multiple healthcare settings—not all of which operate at the same level of research maturity.

Decision-making latency. Multiple layers between sponsor, CRO, and site can be fatal in fast-moving ID programs. By the time changes are approved, the opportunity has passed.

What’s changing: smarter infectious disease trial strategy

Leading infectious disease programs are shifting away from rigid, one-size-fits-all clinical models toward integrated, regionally intelligent trial strategies.

This includes:

• Earlier CRO involvement in protocol design, particularly around feasibility and patient flow
  
• Geography-led recruitment planning, supported by local epidemiology and surveillance expertise to align protocols with real-world incidence, rather than retrofitting global protocols
• Lean operational models that allow rapid decision-making and real-time problem solving
• Closer integration between preclinical insight and clinical execution

These shifts favour CROs that combine scientific depth with operational agility, rather than scale alone.

The Australian advantage in infectious disease research

Australia has emerged as a highly attractive environment for infectious disease clinical research, particularly for early- and mid-phase programs.

Australia offers:

• World-class clinical research infrastructure aligned with international regulatory standards
• High-quality, treatment-naïve patient populations
• Efficient ethics, regulatory and governance pathways, supporting faster trial startup
• Strong translational links between research institutions, hospitals, and industry

Australian CROs, in particular, bring a distinctly collaborative and pragmatic approach to clinical development, one that resonates strongly with global biotech sponsors.

Why flat CRO structures matter in infectious disease trials

In infectious disease research, speed and clarity of decision-making are not luxuries, they are necessities.

Flat CRO structures, such as those adopted by specialist Australian CROs like Molecule2Market, provide tangible advantages:

• Direct access to senior scientific and operational leaders
• Faster protocol refinements based on real-world site feedback
• Reduced communication loss between strategy and execution
• Greater accountability across the trial lifecycle

Rather than navigating multiple layers of account management, sponsors can engage with teams that are deeply embedded in the science and the data, and that are empowered to act quickly.

This model is particularly valuable in infectious disease trials, where recruitment dynamics, safety signals, or external epidemiological shifts may require rapid, informed responses.

Patient recruitment: access over assumptions

Successful infectious disease trials begin and end with patients. Yet recruitment strategies are still too often developed in assumptions, rather than grounded in clinical reality.

Effective patient access in ID trials requires:

• Early feasibility grounded in real incidence data
• Strong hospital and investigator relationships
• Understanding of referral pathways and diagnostic timing
• Flexibility in recruitment models, including targeted regional activation

Australian CROs with established site networks and investigator partnerships are well positioned to deliver reliable recruitment in defined populations, while contributing high-quality data accepted by global regulators.

For global biotechs, this offers a way to de-risk early phases, generate robust proof-of-concept data, and build momentum for later global expansion.

Integrating R&D insight into clinical execution

One of the most underappreciated contributors to infectious disease trial success is the integration of R&D thinking into clinical operations.

When CRO teams understand:

• Mechanism of action
• Translational biomarkers
• Resistance pathways
• Preclinical efficacy signals

They are better equipped to:

• Advise on endpoint selection
• Identify early efficacy or futility signals
• Support adaptive trial decisions
• Ensure data collected is decision-useful, not just compliant

Molecule2Market’s model reflects this integration, one that bridges scientific insight with hands-on execution to support smarter, more efficient clinical development.

Looking ahead: preparedness, not reaction

The next generation of infectious disease threats, whether driven by antimicrobial resistance, climate change, or global mobility, will demand faster, more coordinated clinical research responses.

Biotechs that succeed will be those that:

• Build flexibility into trial design
• Choose CRO partners with genuine infectious disease expertise
• Prioritise patient access and operational agility
• Value collaboration over complexity

In this environment, the right CRO is not simply a service provider, but a strategic partner in risk management and value creation.

For infectious disease programs, smarter trial design is no longer optional. It is the difference between promise and progress.